Joseph E Tomaszewski
Overview
Explore the profile of Joseph E Tomaszewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pfister T, Hollingshead M, Kinders R, Zhang Y, Evrard Y, Ji J, et al.
PLoS One
. 2013 Jan;
7(12):e50494.
PMID: 23284638
Background: Topoisomerase I (Top1) is a proven target for cancer therapeutics. Recent data from the Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing (FOCUS) trial demonstrated that nuclear staining of Top1 correlates...
12.
Behrsing H, Furniss M, Davis M, Tomaszewski J, Parchment R
Toxicol Sci
. 2012 Nov;
131(2):470-9.
PMID: 23143926
The anticancer drug (2-[4-amino-3-methylphenyl]-5-fluorobenzothiazole lysylamide dihydrochloride) (NSC 710305, Phortress) is a metabolically activated prodrug that causes DNA adduct formation and subsequent toxicity. Preclinically, it was found that hepatic, bone marrow,...
13.
Kummar S, Chen A, Parchment R, Kinders R, Ji J, Tomaszewski J, et al.
BMC Med
. 2012 Mar;
10:25.
PMID: 22401667
The poly (ADP-ribose) polymerase (PARP) family of enzymes plays a critical role in the maintenance of DNA integrity as part of the base excision pathway of DNA repair. PARP1 is...
14.
Kummar S, Ji J, Morgan R, Lenz H, Puhalla S, Belani C, et al.
Clin Cancer Res
. 2012 Feb;
18(6):1726-34.
PMID: 22307137
Purpose: Oral administration of the alkylating agent cyclophosphamide at low doses, metronomic dosing, is well tolerated, with efficacy in multiple tumor types. PARP inhibition potentiates effects of cyclophosphamide in preclinical...
15.
Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski J, Kummar S, et al.
Cell Cycle
. 2011 Nov;
10(23):4074-82.
PMID: 22101337
Targeting DNA repair with poly(ADP-ribose) polymerase (PARP) inhibitors has shown a broad range of anti-tumor activity in patients with advanced malignancies with and without BRCA deficiency. It remains unclear what...
16.
Ji J, Kinders R, Zhang Y, Rubinstein L, Kummar S, Parchment R, et al.
PLoS One
. 2011 Oct;
6(10):e26152.
PMID: 22028822
Background: Poly(ADP-ribose) polymerase (PARP) facilitates DNA repair and PARP inhibitors may potentiate the effect of DNA-damaging chemotherapeutic agents in patients with cancer. Collection of peripheral blood mononuclear cells (PBMCs) as...
17.
Kummar S, Chen A, Ji J, Zhang Y, Reid J, Ames M, et al.
Cancer Res
. 2011 Jul;
71(17):5626-34.
PMID: 21795476
A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan, a topoisomerase I-targeted agent, was carried out to determine maximum tolerated dose (MTD), safety, pharmacokinetics, and...
18.
Terse P, Johnson J, Hawk M, Ritchie G, Ryan M, Vasconcelos D, et al.
Toxicol Pathol
. 2011 May;
39(4):614-22.
PMID: 21558467
ST-20 (sodium 2,2-dimethylbutyrate) is a potential therapeutic agent for treatment of β-thalassemia and sickle cell disease. A subchronic oral toxicity study was conducted in Sprague-Dawley rats (10/sex/dose) at gavage dosages...
19.
Trimble E, Abrams J, Ansher S, Smith M, Zwiebel J, Tomaszewski J
Future Med Chem
. 2011 Mar;
2(4):555-9.
PMID: 21426005
No abstract available.
20.
Reid J, Buhrow S, Kuffel M, Jia L, Spanswick V, Hartley J, et al.
Cancer Chemother Pharmacol
. 2010 Dec;
68(3):777-86.
PMID: 21188379
Purpose: The dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501, SG2000) has potent in vitro antiproliferative activity and in vivo antitumor activity associated with binding in the minor groove of DNA and formation...